Pfizer Denied Interlocutory Appeal In Pay-For-Delay MDL

Law360, New York (September 10, 2013, 9:01 PM ET) -- A Tennessee federal judge Tuesday rejected a bid by Pfizer Inc.'s King Pharmaceuticals LLC and Mutual Pharmaceutical Co. to appeal his finding that antitrust claims accusing them of blocking the release of a generic version of the drug Skelaxin were exempt from the statute of limitations.

U.S. District Judge Curtis Collier denied an attempt by the drug makers — which are facing multidistrict litigation over a pay-for-delay deal deferring Mutual's introduction of its generic form of the muscle relaxant — to file an interlocutory appeal of...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required